Cargando…
Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
Ewing sarcoma (ES) is a rare and aggressive disease that requires multidisciplinary treatment with the use of chemotherapy, radiotherapy, and surgery. Our retrospective study aimed to analyze the prognostic factors and treatment results in different age groups of patients. Between 1998 and 2018, 569...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397138/ https://www.ncbi.nlm.nih.gov/pubmed/34441922 http://dx.doi.org/10.3390/jcm10163627 |
_version_ | 1783744547251027968 |
---|---|
author | Jagodzińska-Mucha, Paulina Raciborska, Anna Koseła-Paterczyk, Hanna Kozak, Katarzyna Bilska, Katarzyna Świtaj, Tomasz Falkowski, Sławomir Dawidowska, Anna Rutkowski, Piotr Ługowska, Iwona |
author_facet | Jagodzińska-Mucha, Paulina Raciborska, Anna Koseła-Paterczyk, Hanna Kozak, Katarzyna Bilska, Katarzyna Świtaj, Tomasz Falkowski, Sławomir Dawidowska, Anna Rutkowski, Piotr Ługowska, Iwona |
author_sort | Jagodzińska-Mucha, Paulina |
collection | PubMed |
description | Ewing sarcoma (ES) is a rare and aggressive disease that requires multidisciplinary treatment with the use of chemotherapy, radiotherapy, and surgery. Our retrospective study aimed to analyze the prognostic factors and treatment results in different age groups of patients. Between 1998 and 2018, 569 patients with ES were treated in two referral centers. The patients were divided into four age groups (≤10 years; 11–18 years; 19–25, and >25). The treatment results and prognostic factors were assessed for each group. For statistical analyses, we used the Chi2 test, the Kaplan–Meier estimator with a log-rank test, and the multivariate Cox model. Five-year overall survival (OS) rate was 56%. In the age subgroups: ≤10 years, 11–18 years, 19–25 years, and >25 years, the 5-year OS rates were 75%, 58%, 41%, and 52%, respectively. Favorable prognostic factors: female gender (p = 0.024), non-axial localization (p = 0.005), VIDE regimen (p < 0.001), and surgery as a local treatment (p < 0.001) dominated in the group ≤10 years. In multivariate analysis, male (HR = 1.53), axial localization (HR = 1.46), M1 status at presentation (HR = 2.64), and age > 10 years (HR = 2.29) were associated with shorter OS. The treatment results in ES are significantly better in children aged ≤10 years; the challenge is to provide therapy for adolescents and young adults. The diagnostics and treatment of ES patients must be provided in referral centers. |
format | Online Article Text |
id | pubmed-8397138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83971382021-08-28 Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience Jagodzińska-Mucha, Paulina Raciborska, Anna Koseła-Paterczyk, Hanna Kozak, Katarzyna Bilska, Katarzyna Świtaj, Tomasz Falkowski, Sławomir Dawidowska, Anna Rutkowski, Piotr Ługowska, Iwona J Clin Med Article Ewing sarcoma (ES) is a rare and aggressive disease that requires multidisciplinary treatment with the use of chemotherapy, radiotherapy, and surgery. Our retrospective study aimed to analyze the prognostic factors and treatment results in different age groups of patients. Between 1998 and 2018, 569 patients with ES were treated in two referral centers. The patients were divided into four age groups (≤10 years; 11–18 years; 19–25, and >25). The treatment results and prognostic factors were assessed for each group. For statistical analyses, we used the Chi2 test, the Kaplan–Meier estimator with a log-rank test, and the multivariate Cox model. Five-year overall survival (OS) rate was 56%. In the age subgroups: ≤10 years, 11–18 years, 19–25 years, and >25 years, the 5-year OS rates were 75%, 58%, 41%, and 52%, respectively. Favorable prognostic factors: female gender (p = 0.024), non-axial localization (p = 0.005), VIDE regimen (p < 0.001), and surgery as a local treatment (p < 0.001) dominated in the group ≤10 years. In multivariate analysis, male (HR = 1.53), axial localization (HR = 1.46), M1 status at presentation (HR = 2.64), and age > 10 years (HR = 2.29) were associated with shorter OS. The treatment results in ES are significantly better in children aged ≤10 years; the challenge is to provide therapy for adolescents and young adults. The diagnostics and treatment of ES patients must be provided in referral centers. MDPI 2021-08-17 /pmc/articles/PMC8397138/ /pubmed/34441922 http://dx.doi.org/10.3390/jcm10163627 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jagodzińska-Mucha, Paulina Raciborska, Anna Koseła-Paterczyk, Hanna Kozak, Katarzyna Bilska, Katarzyna Świtaj, Tomasz Falkowski, Sławomir Dawidowska, Anna Rutkowski, Piotr Ługowska, Iwona Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience |
title | Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience |
title_full | Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience |
title_fullStr | Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience |
title_full_unstemmed | Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience |
title_short | Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience |
title_sort | age as a prognostic factor in patients with ewing sarcoma—the polish sarcoma group experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397138/ https://www.ncbi.nlm.nih.gov/pubmed/34441922 http://dx.doi.org/10.3390/jcm10163627 |
work_keys_str_mv | AT jagodzinskamuchapaulina ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT raciborskaanna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT kosełapaterczykhanna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT kozakkatarzyna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT bilskakatarzyna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT switajtomasz ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT falkowskisławomir ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT dawidowskaanna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT rutkowskipiotr ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience AT ługowskaiwona ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience |